CoChat

Cardiac metabolism as a driver and therapeutic target of myocardial infarction

Open access
Zuurbier, Coert J., Bertrand, Luc, Beauloye, Christoph R., Andreadou, Ioanna, Ruiz‐Meana, Marisol, Jespersen, Nichlas R., Kula‐Alwar, Duvaraka, Prag, Hiran A., Eric Botker, Hans, Dambrova, Maija, Montessuit, Christophe, Kaambre, Tuuli, Liepinsh, Edgars, Brookes, Paul S., Krieg, Thomas · 2020 · Journal of Cellular and Molecular Medicine
Cited by 236

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Reducing infarct size during a cardiac ischaemic‐reperfusion episode is still of paramount importance, because the extension of myocardial necrosis is an important risk factor for developing heart failure. Cardiac ischaemia‐reperfusion injury (IRI) is in principle a metabolic pathology as it is caused by abruptly halted metabolism during the ischaemic episode and exacerbated by sudden restart of specific metabolic pathways at reperfusion. It should therefore not come as a surprise that therapy directed at metabolic pathways can modulate IRI. Here, we summarize the current knowledge of important metabolic pathways as therapeutic targets to combat cardiac IRI. Activating metabolic pathways such as glycolysis (eg AMPK activators), glucose oxidation (activating pyruvate dehydrogenase complex), ketone oxidation (increasing ketone plasma levels), hexosamine biosynthesis pathway (O‐GlcNAcylation; administration of glucosamine/glutamine) and deacetylation (activating sirtuins 1 or 3; administration of NAD+‐boosting compounds) all seem to hold promise to reduce acute IRI. In contrast, some metabolic pathways may offer protection through diminished activity. These pathways comprise the malate‐aspartate shuttle (in need of novel specific reversible inhibitors), mitochondrial oxygen consumption, fatty acid oxidation (CD36 inhibitors, malonyl‐CoA decarboxylase inhibitors) and mitochondrial succinate metabolism (malonate). Additionally, protecting the cristae structure of the mitochondria during IR, by maintaining the association of hexokinase II or creatine kinase with mitochondria, or inhibiting destabilization of F O F 1‐ATPase dimers, prevents mitochondrial damage and thereby reduces cardiac IRI. Currently, the most promising and druggable metabolic therapy against cardiac IRI seems to be the singular or combined targeting of glycolysis, O‐GlcNAcylation and metabolism of ketones, fatty acids and succinate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcmm.15180

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 236

Metadata

Authors
Zuurbier, C. J., Bertrand, L., Beauloye, C. R., Andreadou, I., Ruiz‐Meana, M., Jespersen, N. R., Kula‐Alwar, D., Prag, H. A., Eric Botker, H., Dambrova, M., Montessuit, C., Kaambre, T., Liepinsh, E., Brookes, P. S., & Krieg, T.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2020-05-08
Volume
24
Issue
11
Pages
5937-5954
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W3022223885
Cited by
236
References
22
FWCI
14.14
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiac metabolism as a driver and therapeutic target of myocardial infarction. https://app.cochat.ai/papers/10.1111/jcmm.15180
The paper
Zuurbier, C. J., Bertrand, L., Beauloye, C. R., Andreadou, I., Ruiz‐Meana, M., Jespersen, N. R., Kula‐Alwar, D., Prag, H. A., Eric Botker, H., Dambrova, M., Montessuit, C., Kaambre, T., Liepinsh, E., Brookes, P. S., & Krieg, T. (2020). Cardiac metabolism as a driver and therapeutic target of myocardial infarction. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.15180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.